The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! About 186,402 shares traded hands. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 99.88% since March 3, 2016 and is uptrending. It has outperformed by 91.53% the S&P500.
The move comes after 6 months positive chart setup for the $728.50 million company. It was reported on Oct, 6 by Barchart.com. We have $24.71 PT which if reached, will make NASDAQ:VNDA worth $342.40 million more.
Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on November, 1. They expect $-0.15 earnings per share, up 6.25% or $0.01 from last year’s $-0.16 per share. After $-0.04 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 275.00% negative EPS growth.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage
Out of 4 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vanda Pharmaceuticals has been the topic of 5 analyst reports since September 2, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Piper Jaffray on Wednesday, September 2. JMP Securities maintained the stock with “Market Outperform” rating in Friday, August 26 report. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Brean Capital on Wednesday, October 21.
According to Zacks Investment Research, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.”
Insitutional Activity: The institutional sentiment increased to 1.02 in 2016 Q2. Its up 0.10, from 0.92 in 2016Q1. The ratio increased, as 19 funds sold all Vanda Pharmaceuticals Inc. shares owned while 33 reduced positions. 19 funds bought stakes while 34 increased positions. They now own 36.20 million shares or 6.54% less from 38.73 million shares in 2016Q1.
First Mercantile holds 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 8,860 shares. Jane Street Gp Limited Co has 0% invested in the company for 17,873 shares. Goldman Sachs Grp Incorporated accumulated 0% or 347,886 shares. State Street holds 1.29 million shares or 0% of its portfolio. Palo Alto Limited Liability Corporation accumulated 4.23M shares or 3.57% of the stock. Deerfield Management Company accumulated 6.00 million shares or 2.64% of the stock. The New York-based Qs Lc has invested 0.04% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Numeric Invsts Ltd Limited Liability Company has 0% invested in the company for 42,900 shares. Pnc Service accumulated 1,000 shares or 0% of the stock. Blackrock Group Limited holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 23,537 shares. Gagnon Ltd Liability Com accumulated 40,897 shares or 0.22% of the stock. Ajo L P accumulated 195,915 shares or 0.01% of the stock. Deutsche Financial Bank Ag last reported 326,765 shares in the company. Renaissance Technology Ltd Liability has 151,050 shares for 0% of their US portfolio. Northern Tru Corporation, a Illinois-based fund reported 482,597 shares.
Insider Transactions: Since September 15, 2016, the stock had 0 insider purchases, and 2 selling transactions for $27.14 million net activity. Shares for $8.58M were sold by Flynn James E.
More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Reuters.com which released: “Exclusive: Vanda Pharmaceuticals prepares to explore a sale – sources” on September 22, 2016, also Prnewswire.com with their article: “Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results” published on July 27, 2016, 247Wallst.com published: “Massive Facebook Trade Highlights Insider Selling: Apple, Adobe, Copart, Vanda …” on October 02, 2016. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Fool.com and their article: “Why Tiffany, AEP Industries, and Vanda Pharmaceuticals Jumped Today” published on August 25, 2016 as well as Prnewswire.com‘s news article titled: “Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results” with publication date: May 04, 2016.
VNDA Company Profile
Vanda Pharmaceuticals Inc., incorporated on November 13, 2002, is a biopharmaceutical company. The Firm is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.